



# Reblozyl in Kuwait

*The Kuwait MOH named-patient coordination pathway — indicative 2026*

HEMATOLOGY · TRANSFUSION-DEPENDENT ANEMIA

## The clinical situation

Reblozyl (luspatercept-aamt) is an FDA-approved TGF-beta superfamily ligand trap indicated for anemia in transfusion-dependent beta-thalassemia and lower-risk myelodysplastic syndromes with ring sideroblasts. Manufactured by Bristol Myers Squibb. Administered by subcutaneous injection every 3 weeks with weight-based dosing. Requires 2–8°C cold-chain storage.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating hematologist confirms transfusion-dependent status and documents the clinical rationale and weight-based dosing plan.
- 2 Administration site confirmed.** A Kuwaiti hematology clinic or tertiary hospital accepts the case for every-3-week supervised injections.
- 3 Kuwait MOH named-patient application.** Clinical rationale, patient reference, product details, weight-based dose, and cold-chain plan filed with the Ministry of Health.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner on validated 2–8°C cold-chain.
- 5 Arrival & administration.** The clinic receives the dose under temperature-monitored handling; maintenance doses every 3 weeks.

### Indicative economics

**Reference US cash-pay range:** USD 8,000–10,000 per 3-week dose (weight-based). Cold-chain logistics, Kuwait MOH documentation, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete Kuwait MOH application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and Kuwait MOH review. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating hematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Reblozyl × Kuwait first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/reblozyl-kuwait.html](https://reservemed.com/access-guides/reblozyl-kuwait.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team